Inhibikase Therapeutics Inc — Cash Flow (NASDAQ:IKT) | MetaTrader

Open full chart

Financials

Overview Statement Statistics Dividends

Quarterly Annual

Cash from operating activities -14.3 M-17.35 M-18.09 M-19.15 M -25.62 M Cash from investing activities —-16.01 M11.66 M-37 M -36.61 M Cash from financing activities 41.09 M-204.77 K8.41 M103.48 M 99.58 M Free cash flow -14.3 M-17.59 M-18.1 M-19.15 M -25.63 M

News

BofA Securities initiates coverage on Inhibikase stock with Buy rating

Jefferies reiterates Buy rating on Inhibikase stock, citing faster FDA path

H.C. Wainwright assumes coverage on Inhibikase stock with Buy rating

Monday’s Insider Activity: Top Executives Trade Shares at Tech Giants

Why Intuit Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket - Gap (NYSE:GAP), Elastic (NYSE:ESTC)

Inhibikase Therapeutics prices $100 million public offering

Inhibikase Therapeutics stock falls after announcing public offering

Inhibikase Posts Wider Loss in Q2

Inhibikase Therapeutics shareholders elect directors and approve equity plan changes

Ludwig Enterprises appoints Garth Lees-Rolfe as independent director

Inhibikase Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Activity

This PPG Industries Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday - Inhibikase Therapeutics (NASDAQ:IKT), Axcelis Technologies (NASDAQ:ACLS)